Monday, November 24, 2014 Last update: 4:03 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei

Companies mentioned in this article: GenSpera, Inc.

SAN ANTONIO, July 7, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13(th) in Taipei, Taiwan.

An oral presentation entitled, "Clinical Activity of G-202, a Thapsigargin-Based Prostate-Specific Membrane Antigen (PSMA)-Activated Prodrug, in Patients with Progressive Hepatocellular Carcinoma (HCC)" will be presented in the poster discussion session "Treatment for Intermediate - Advanced Stage Disease" on July 12(th) from 1:15- 3:00 pm UTC + 8:00.

Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC), will discuss the data obtained to date in patients with HCC treated in the Phase I and Phase II studies. Dr. Mahalingam is an oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, specializing in identifying novel cancer therapeutics.

The abstract will be published on the company website following the APPLE Poster Session.

About Asia-Pacific Primary Liver Cancer Expert
http://www.2014applecongress.org/

About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

    CONTACT:


    Company:                  Craig Dionne, PhD, CEO

                              GenSpera, Inc.  (210) 479-8112


    Investors:                John Baldissera

                               BPC Financial Marketing (800)
                               368-1217


    Media:                                    (800) 665 0411

SOURCE GenSpera, Inc.